LAS VEGAS, NV / ACCESSWIRE / February 3, 2016 / The most notable of the pack is Propanc Health Group Corporation (PPCH), which is an exciting, young company within the sector. Propanc, whose focus is the development of new and proprietary treatments for cancer patients suffering from pancreatic, ovarian and colorectal cancers, recently announced the Company received a further $525,000 tranche from an institutional investor in order to progress their lead product, PRP, towards human trials. PPCH has already grabbed the attention of more than a few investors thanks to the Company's substantial growth in 2015 and expected growth in 2016.
Propanc's leading product, PRP, is a patented formulation composed of proteolytic (protein digesting) proenzymes, which are activated at the tumor site, then alter the pathways in and around the cancer cell, turning cancerous cell back towards a benign (non-threatening) state. Based on laboratory research at the Universities of Bath, Granada and Jaѐn with also additional limited experiences with late stage cancer patients via a compassionate use program, evidence suggests that PRP could be an effective long term therapy for the treatment and prevention of metastatic cancer. The limited patient experience with the therapy identified two notable advantages of PRP compared to other cancer treatments: they were able to meaningfully extend life in a number of late stage cancer patients suffering from aggressive cancers who had failed conventional treatment and patients showed no observable severe, or even serious adverse reactions to the formulation.
Propanc has stated that its current clinical findings of PRP must be confirmed in formal clinical trials, but data suggests that proenzyme therapy has the potential to meaningfully extend life in terminally ill patients without the side effects normally associated with standard treatment approaches. To date, researchers have found no evidence that patients develop resistance to PRP, and as a result, the product seems suitable for long-term treatment.
The Company is aiming to expedite the development of PRP products into clinical trials in the near future. It is already preparing for a meeting with the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, before the end of the first quarter of 2016 to discuss the possibility of initiating clinical trials late 2016, or early 2017. The meeting will focus on Propanc's planned animal safety toxicology studies, as well as early stage clinical development of PRP.
Propanc received a substantial $525,000 in funds from an institutional investor in mid-January with the goal of advancing their product, PRP, toward human trials. According to Global Analyst Reports, the market for colorectal cancer treatment is expected to reach approximately $8.8 billion by 2020, and the market for pancreatic cancer is expected to exceed $1.2 billion in 2015.
To date, the Propanc has received $2.4 million from the institutional investor as of Oct. 28, when the Securities Purchase Agreement, Debenture, and Warrant was executed. The balance of the investment amount totaling $1.6 million is set to be paid in the future, totaling $4 million, and the Company's current cash position is nearly $1.2 million.
The company is looking like a strong choice for investors in 2016; it has a Relative Strength Index (RSI) of 34.43 and has been trading at a volume of 3.09 million shares. It has seen a 53-week high of USD 0.1338 and making investors incredible gains with a low of USD 0.0021.
As important milestones are reached throughout 2016 and 2017, stock prices are expected to rise and present a great opportunity for investors. Not only is Propanc focused on improving the lives of individuals suffering from colorectal and pancreatic cancers, but its recent funding instalment has ensured that the Company is secure enough to begin the next stage of its clinical research in the near future.
We believe the Biotech sector is going to experience some of the largest turnaround gains for investors of all sizes. Here are some more notable companies to watch:
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) hit a major milestone in the first part of January when it announced that the Psychopharmacologic Drugs Advisory Committee (PDAC) of the U.S. Food and Drug Administration (FDA) had voted 12 to 5 in favor of approving Probuphine. This is the first long-acting subdermal buprenorphine implant for the treatment of opioid addictions in patients receiving 8mg or less per day of buprenorphine. President and CEO Sunil Bhonsle stated that Probuphine "could increase patient compliance, decrease the risk of diversion and improve patients' quality of life" because it has the potential to provide six months of maintenance treatment in just one procedure.
Another biopharmaceutical company, TetraLogic Pharmaceuticals Corp. (NASDAQ: TLOG), is in its clinical stages of developing small molecule therapeutics in oncology and infectious diseases. It recently announced the interim analyses of two clinical studies at the beginning of January: The first tested the effectiveness of birinapant co-administered with azacitidine. This showed no significant clinical benefit over placebo in high-risk patients suffering from myelodysplastic syndromes (MDS), and the study will be terminated. This likely contributed to Tetralogic's trading move of (-85%) from $2.19 to $0.32. The second study analyzed the effectiveness of SHAPE, a topical HDAC inhibitor, and this study proved a clinical benefit in the randomized Phase 2 CTCL study.
In December, Raptor Pharmaceuticals Corp. (NASDAQ: RPTP) presented 36-month efficacy data of RP103 for the treatment of patients with Huntington's disease. The study is in collaboration with Centre Hospitalier Universitaire in d'Angers, France. The data showed a consistent improvement of functional measures, and the Company is likely to seek regulatory guidance on the development of RP103 in the U.S. and E.U. in the near future. Raptor saw a 52-week high of $16.28 and a 52-week low of $2.94, with a three-month trading volume of 1.19 million shares.
And finally, MannKind Corp. (NASDAQ: MNKD) announced that it just signed a collaboration and license agreement with Receptor Life Sciences, Inc. as it develops new inhaled products for conditions involving chronic pain, inflammatory diseases, and neurologic diseases. MannKind is eligible to receive up to $102.25 million in development and commercialization milestones. It saw a pretty steep fall in shares right after announcing the termination of its collaboration and license agreement with Sanofi SNY for the development and commercialization of Afrezza, but the new deal with Receptor is likely to set MannKind back on the right path.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.commay from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC. has been compensated $37,000 by Propanc Health Group, Corp. for this news article and for previous as well as future news articles.
Contact:
SOURCE: ACR Communication, LLC
